Combining proteasome inhibitors with autophagy inhibitors disrupts acute myeloid leukemia (AML) cells' proteostasis, enhancing treatment efficacy and inducing programmed cell death. A novel ...

A cross-continental study suggests that in the treatment of acute myeloid leukemia, age affects survival, independent of genetic-risk groups.

M2T-CD33 (LTI-214) has received FDA orphan drug designation, offering incentives like tax credits and market exclusivity for AML treatment. The treatment targets CD33, a glycoprotein present in 90% of ...

Panelists discuss how the treatment landscape has evolved from limited options to include hypomethylating agents and ...

Detailed price information for Astellas Pharma Inc (ALPMF) from The Globe and Mail including charting and trades.

Anthracycline and cytarabine chemotherapy has been the backbone of induction chemotherapy for AML for more than 50 years. Advances in our understanding of leukemia biology and the development of ...

Oral therapy options in oncology are increasingly valued for their convenience, reduced need for intravenous access, and ...

Acute myeloid leukemia (AML) is a type of blood and bone marrow cancer. AML can affect people of any age, but it is most common in adults. AML occurs when bone marrow produces abnormal blood cells, ...

Acute myeloid leukemia driven by tandem duplications within the UBTF gene (UBTF-TD AML) is a high-risk pediatric cancer in ...

The ASAP trial shows immediate transplantation matches chemotherapy outcomes in AML, with genetics driving survival differences.